

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF: Thomas A. Beyer, et al. : Confirmation No.: 6301  
  
APPLICATION NO.: 10/595,766 : Examiner: Jaisle, Cecilia M.  
  
FILING DATE: 05-10-2006 : Group Art Unit: 1614  
  
TITLE: Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 :  
inhibitors  
-----

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: October 17, 2007

/ Lyman H. Smith /

Lyman H. Smith  
Attorney for Applicant(s)  
Reg. No. 44,342

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-2372